UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

 

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

For the month of November, 2018

 

Commission File Number: 001-36000

 

XTL Biopharmaceuticals Ltd.

(Translation of registrant’s name into English)

 

5 Badner St.

Ramat Gan,
4365603, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒      Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

 

 

 

 

 

 

The management of XTL Biopharmaceuticals Ltd. will be presenting at an investor conference on November 11, 2018. A copy of the presentation is furnished as Exhibit 99.1 to this Report on Form 6-K.

 

  1  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  XTL BIOPHARMACEUTICALS LTD.
   
Date: November 8, 2018 By: /s/ Josh Levine
    Josh Levine
    Chief Executive Officer

 

  2  

 

 

Exhibit Index

 

Exhibit
Number

 

Exhibit Title

   
99.1   XTL Biopharmaceuticals Ltd. Investor Presentation

 

  3  

XTL Biopharmaceuticals (NASDAQ:XTLB)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025 Haga Click aquí para más Gráficas XTL Biopharmaceuticals.
XTL Biopharmaceuticals (NASDAQ:XTLB)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025 Haga Click aquí para más Gráficas XTL Biopharmaceuticals.